Loading data for CTOR — first visit, this takes a few seconds.

Preisalarm

Citius Oncology Inc. (CTOR)

NasdaqCM: CTOR · Echtzeitkurs · USD

0.74

-0.18 (-19.57%)

Zum Schluss: Aug 19, 2026, 1:06 PM

-19.57% (1D)

Geld	0.54
Marktkapitalisierung	79.33 Mio
Umsatz (TTM)	5.61 Mio
Nettogewinn (TTM)	-42.51 Mio
Beta	3.49
EPS (ttm)	-0.48
KGV (TTM)	n/a
Forward-KGV	n/a
KBV (TTM)	1.98
KUV (TTM)	14.14
Earnings Date	n/a

Brief	0.98
Volumen	274,784
Ø Vol. (20D)	80,365
Eröffnung	0.77
Vortagesschluss	0.92
Tagesspanne	0.70 - 0.78
52-Wk Range	0.49 - 2.25
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über CTOR

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc....

[Mehr lesen]

Branche Drug Manufacturers - Specialty & Generic

Sektor Healthcare

IPO Datum Dec 8, 2022

Mitarbeiter n/a

Börse NasdaqCM

Tickersymbol CTOR

Website https://citiusonc.com/overview/default.aspx

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Citius Oncology 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -24.76 Mio, ein Anstieg von 17.08 %.

Finanzberichte

Gewinnüberraschung

Citius Oncology hat die Quartalszahlen am Aug 14, 2026 veröffentlicht:

Umsatz von $1.67 Mio verfehlt die Erwartungen um $0, mit Infinity% Wachstum im Jahresvergleich.

EPS von -0.08 verfehlt die Erwartungen um -0.01, mit 0.00% Wachstum im Jahresvergleich.

Nachrichten

vor 2 Tagen · InvestorsHub

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology Inc. (NASDAQ:CTOR) shares fell 10.

vor 2 Monaten · Insider Monkey

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?

With an upside potential of 843.40%, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 18, H.C. Wainwright analyst Sway...

vor 3 Monaten · Pharmaceutical Technology

Citius raises $36.5m for Lymphir commercialisation

The capital includes a $25m term loan and a warrant exercise agreement expected to yield $11.5m.

vor 4 Monaten · Simply Wall St.

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)

Citius Oncology, Inc. ( NASDAQ:CTOR ) is possibly approaching a major achievement in its business, so we would like to...

vor 5 Monaten · Insider Monkey

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following...

Seite 1 von 2

Citius Oncology Inc. (CTOR)